SS Innovations International, Inc. (SSII) is a Nasdaq-listed, Fort Lauderdale-domiciled surgical robotics company that develops the SSi Mantra multi-arm robotic surgery system and the SSi Mudra instrument suite, with the vast majority of revenue generated in India. The stock was trading at $1.25 shortly after Tuesday's opening bell, a decline of 7.41%, or $0.10, from Monday's close of $1.35. Direction is clearly negative. The immediate reason markets are selling is the company's third-quarter financial report, released after Monday's close, which showed quarterly revenue collapsing year over year and repeated substantial doubt about the company's ability to continue as a going concern.
The quarter was the decisive problem. Revenue fell to $6.33 million from $12.83 million a year earlier, a 50.7% decline and well short of the roughly $15 million analysts had modeled. System sales were the weak spot, dropping to $4.72 million from $11.71 million, as the company shifted emphasis toward multi-system deals with hospital operators and government health agencies — negotiations that take longer to convert. Gross profit fell 49.6% to $3.11 million, though gross margin edged up to 49.1% from 48.1%.
Operating costs moved the wrong way at the same time. The operating loss widened to $6.06 million from $1.84 million, with research and development spending more than tripling to $2.51 million as the company funded clinical and regulatory work tied to U.S. and European clearances. Net loss widened to $5.75 million, or $0.03 per share, from $3.72 million, or $0.02 per share. Nine-month revenue of $31.41 million was still up 12.4%, but a quarter that halves sequentially breaks the growth narrative that has supported the equity.
The filing renewed a warning that has weighed on the shares all year. Management flagged substantial doubt about the company's ability to continue as a going concern, with an accumulated deficit of $67.8 million, cash and equivalents of $8.1 million plus $10.5 million of restricted cash at September 30, and $16.9 million of short-term borrowings. Receivables stood at $24.1 million, much of it financed on multi-year terms. Management said it intends to raise additional capital this year, and the company also disclosed a material weakness in internal control over financial reporting.
That funding risk is already priced into the share count. In October the company closed a $20 million secured convertible note carrying an 8.75% coupon and secured by its intellectual property, an instrument whose conversion mechanics can add supply if the stock weakens — a self-reinforcing dynamic that tends to accelerate declines rather than cushion them.
The U.S. approval, viewed by investors as the single largest value driver, remains unresolved. Last week the company said it is responding to all queries raised by the Food and Drug Administration during review of its 510(k) premarket notification for the SSi Mantra while pursuing CE marking in Europe. Expectations now center on a decision in the first quarter of 2027 for an initial cholecystectomy indication. That timeline helped spark a sharp one-day rally late last week, which was fully reversed on Monday when the stock fell 18.7% — a reminder that headline-driven spikes in this name have not held.
Turnover has been heavy relative to the stock's normal pace, with Monday's session of roughly 342,000 shares far above a three-month average near 80,000. The move pushed the shares to a new 52-week low of $1.15 intraday, beneath the prior floor of $1.26 and a long way from the 52-week high of $6.79. Price sits below every major moving average, and with a public float of about 40 million shares the order book is thin enough that modest block trades move the tape by several percentage points; the stock rebounded from $1.15 to above $1.28 within minutes on small prints. There was no matching industry or macro event, and the decline was concentrated in this one name rather than in surgical robotics broadly.
The scale runs from 0, meaning no meaningful news and a move that is normal for the stock, to 100, meaning transformative news and an extreme, rare price move. This event scores 46 out of 100. The verified news was clearly material: a 50.7% revenue decline in the quarter, a loss that more than doubled, and renewed going-concern disclosure are significant developments for a company of this size. The price reaction, however, was not exceptional by this stock's own standards — the decline was about 2.1 times its typical daily move of roughly 3.5%, and moves of this magnitude or larger have occurred eight times in the past 60 sessions. Strong news, unremarkable volatility for the name, and a mid-range score as a result.
Attention turns to the fourth quarter, where investors will look for evidence that the delayed multi-system contracts convert into recognized revenue and that pay-per-use placements translate into recurring instrument sales. The FDA 510(k) decision, now guided to the first quarter of 2027, and progress toward EU CE marking are the two binary regulatory events. Coverage remains thin, so single research notes can move sentiment disproportionately. The central risk is financing: with a stated need for additional capital, any equity raise would dilute existing holders, while any further delay on approvals extends the cash burn. Receivables quality, gross margin retention and the pace of system installations are the operating metrics to track.
Tickeron operates hundreds of AI trading bots covering thousands of tickers, and the Trending AI Robots page narrows that universe to the strategies performing strongest under present market conditions. Bots differ widely by strategy, timeframe, performance metrics and the symbols they trade, so the curated list offers a practical starting point for comparing approaches. Investors looking for systematic exposure to volatile small caps like this one may find the section a useful reference.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where SSII declined for three days, in 124 of 134 cases, the price declined further within the following month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for SSII turned negative on November 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 39 similar instances when the indicator turned negative. In 29 of the 39 cases the stock turned lower in the days that followed. This puts the odds of success at 74%.
The Aroon Indicator for SSII entered a downward trend on November 16, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Indicator entered the oversold zone -- be on the watch for SSII's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +11.11% 3-day Advance, the price is estimated to grow further. Considering data from situations where SSII advanced for three days, in 62 of 95 cases, the price rose further within the following month. The odds of a continued upward trend are 65%.
SSII may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron Valuation Rating of 56 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (10.846) is normal, around the industry mean (4.142). P/E Ratio (0.000) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (12.887) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 92 (best 1 - 100 worst), indicating slightly worse than average price growth. SSII’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 99 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SSII’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry MedicalNursingServices